to the emergency department, where she was treated with diuretics and corticosteroids, without improvement. An immunological study revealed a very low C4 serum level (2.2 mg/dL), normal antigenic C1-INH (16.2 mg/dL), low C1-INH function (25.7%), and normal serum C1q (157.95 mg/dL). Sequencing of the C1-INH and F12 genes revealed no pathogenic variants. She was initially diagnosed with C1-INH-HAE and was referred to the angioedema unit of a tertiary hospital, where her diagnosis was changed to C1-INH-AAE because of the presence of anti-C1-INH IgG autoantibodies. An exhaustive study was performed, and lymphoproliferative disorder was excluded. Additional autoimmunity tests showed negative results, and a normal peripheral lymphocyte count with 15% NK cells was found. After the diagnosis, the patient was prescribed plasma derived C1-inhibitor concentrate (pdhC1INH) (Berinert, CSL-Behring) to be taken at home. Off-label intravenous pdhC1INH (1000U) was administered for subsequent angioedema episodes, with a good response and no adverse events.
After the failed IVF cycles, the patient underwent egg and sperm donation treatment. One fresh embryo was transferred, resulting in a monochorionic monoamniotic twin pregnancy. She experienced a miscarriage in the eighth week of pregnancy as a complication of the monochorionic monoamniotic twin pregnancy, although this was unrelated to angioedema and pdhC1INH use. Uterine curettage was performed with prior administration of intravenous pdhC1INH 1000U as short-term prophylaxis, with no subsequent angioedema. In the second cycle, natural cycle endometrial preparation was used to transfer another frozen embryo. A single blastocyst was transferred, leading to pregnancy. Surprisingly, the approach resulted in a monochorionic biamniotic twin pregnancy. Adjuvant therapy included intravenous gammaglobulin (Privigen, CSL-Behring) every 3 weeks because of NK percentages [6] and evidence of autoimmunity [7] ; vitamins and ferrous oral supplements were also administered. Autoimmune thyroid dysfunction was first detected at the end of the first trimester, and thyroxin was prescribed. During the second and third trimesters, complement levels returned to normal and no angioedema attacks occurred. The patient underwent cesarean delivery at the 37th week owing to breech presentation, with prior administration of intravenous pdhC1INH 1000U as shortterm prophylaxis. No angioedema developed. The patient gave birth to 2 healthy boys weighing 2900 g and 3100 g with no further obstetrical or neonatal complications. She started breastfeeding immediately, together with artificial lactation, and is currently (21 months after delivery) breastfeeding them twice a day. She remained free of angioedema attacks for 3.5 months after delivery, when she started to experience moderate-severe angioedema episodes at various sites, which were treated with intravenous pdhC1INH 1000U twice a month. She also reported monthly mild abdominal attacks, which resolved spontaneously.
During a short period with frequent angioedema attacks, the patient received long-term prophylaxis with intravenous pdhC1INH every 4 days.
Complement levels, angioedema attacks, and treatments are summarized in the Figure. We report the case of a patient who developed C1-INH-AAE during fertilization therapy. Our initial diagnosis was C1-INH-HAE, since C1q was normal, a mutation in the C1-INH gene is not found in 5%-10% of families with C1-INH-HAE [4] , and up to 25% of patients can have a spontaneous mutation [1, 4] . Subsequently, positive anti-C1-INH antibodies enabled us to make a more accurate diagnosis of C1-INH-AAE. A case of C1-INH-AAE with normal C1q has been reported [8] .
Patients with C1-INH-HAE or C1-INH-AAE can attend a fertility clinic if they cannot become pregnant naturally. They should avoid estrogen treatments, which can lead to an increase in the frequency and severity of angioedema attacks [4] . Therefore, if ovarian stimulation is necessary for IVF, it should be targeted to reach the lower estrogen levels [4] . Besides, pdhC1INH can be used during these procedures in order to reduce the number and severity of angioedema attacks [4] . pdhC1INH is the first-line treatment for C1-INH-HAE during pregnancy [4] and should also be used for C1-INH-AAE. In the case we report, adjuvant therapy with intravenous gammaglobulin may have helped to modulate autoimmune disease, as previously published [6, 7] , with a reduction in antiC1-INH antibody levels, normalization of C1-INH levels and function and C4 levels, and improvement in clinical symptoms.
Also intriguing was the presentation of 2 consecutive monochorionic twin pregnancies after single-embryo transfers. The monochorionic twin pregnancy rate increases by 1%-5% in single-embryo transfer [9] , probably owing to the culture medium, the length of the blastocyst stage, and embryo quality. In a large historical cohort study, where more than 238 000 pregnancies after assisted reproduction techniques were analyzed, only 1 woman had recurrence of monochorionic twin pregnancy, although this was considered to be random [9] . The clinical case here described is unique because C1-INH-AAE, an extremely rare condition, developed during assisted 
